Patents Assigned to Pfizer
  • Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
    Patent number: 7439267
    Abstract: The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from cardiac insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), either alone or in combination with another therapeutic agent.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: October 21, 2008
    Assignee: Pfizer Italia S.R.L.
    Inventors: Francesco Granata, Franco Pamparana, Eduardo Stragliotto
  • Phenol derivative
    Patent number: 7439397
    Abstract: The compound 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(trifluoromethyl) phenol may be used to prepare the compound (3R)-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-N,N-diisopropyl-N-methyl-3-phenylpropan-1-aminium bromide by reaction with methyl bromide.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: October 21, 2008
    Assignee: Pfizer Inc
    Inventors: Ivan Richards, Sue K. Cammarata, Craig D. Wegner, Michael Hawley, Mark Peter Warchol, Mark Kontny, Walter Morozowich, Karen Patrice Kolbasa, Malcolm Wilson Moon, Dominique Bonafoux, Sergey Gregory Wolfson, Patrick James Lennon
  • Substituted arylpyrazoles
    Patent number: 7435753
    Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which there is at least one fluorine attached to the cyclopropyl ring, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: October 14, 2008
    Assignee: Pfizer Limited
    Inventors: Denis Billen, Nathan Anthony Logan Chubb, David Morris Gethin, Kim Thomas Hall, Lee Richard Roberts, Nigel Derek Arthur Walshe
  • Pyrazole derivatives
    Patent number: 7435728
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: October 14, 2008
    Assignee: Pfizer Inc
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Pharmaceutical formulations, methods, and dosing regimens for the treatment and prevention of acute coronary syndromes
    Patent number: 7435717
    Abstract: The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano:phospholipid complex to reduce and stabilize atherosclerotic plaque. Pharmaceutical formulations of the Apo A-I Milano:phospholipid complexes are also provided.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: October 14, 2008
    Assignee: Pfizer Inc.
    Inventors: Charles L. Bisgaier, Narendra D. Lalwani, Wendi V. Rodrigueza, Daniel Hartman, Jan Johansson
  • Method of treatment for sexual dysfunction
    Patent number: 7432299
    Abstract: Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: October 7, 2008
    Assignee: Pfizer Inc.
    Inventors: Charles Price Taylor, Jr., Andrew John Thorpe, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman, David Juergen Wustrow
  • Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
    Patent number: 7432263
    Abstract: Compounds which are amino-phthalazinone derivatives according to formula 1 and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compostions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: October 7, 2008
    Assignee: Pfizer Italia, S.r.l.
    Inventor: Maurizio Pulici
  • Chiral salt resolution
    Patent number: 7432370
    Abstract: The present application discloses compounds of the formula wherein R2 and R3 are as defined herein. The present application further discloses certain pyrrolol[2,3-d]pyrimidine compounds having the 3R,4R stereochemical configuration shown above. Corresponding pharmaceutical compositions and methods for the treatment or prevention of a disorder or condition selected from organ transplant rejection, xeno transplantation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia and other autoimmune diseases are also disclosed.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: October 7, 2008
    Assignee: Pfizer Inc.
    Inventors: Glenn E. Wilcox, Mark E. Flanagan, Michael J. Munchhof, Ton Vries, Christian Koecher
  • Heteroaromatic quinoline compounds
    Patent number: 7429665
    Abstract: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: September 30, 2008
    Assignee: Pfizer Inc
    Inventors: Patrick R. Verhoest, Christopher J. Helal, Dennis J. Hoover, John M. Humphrey
  • Fluorine NMR spectroscopy for biochemical screening
    Publication number: 20080233603
    Abstract: High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498-505) is extended to the screening of Ser/Thr kinases. The method requires the presence of a CF3 (or CF) moiety on the substrate and utilizes 19F NMR spectroscopy for the detection of the starting and enzymatically modified substrates. Experiments can be performed in real time or in an endpoint assay format using protein and substrate concentrations comparable to the ones used by other HTS techniques. Application of this technique to the phosphorylation of a substrate by the protein Ser/Thr kinase AKT1 is presented.
    Type: Application
    Filed: July 9, 2007
    Publication date: September 25, 2008
    Applicant: Pfizer Italia S.r.l.
    Inventors: Claudio Dalvit, Elena Ardini, Maria Magdalena Flocco, Gianpaolo Fogliatto, Nicola Mongelli, Marina Veronesi
  • Human monoclonal antibodies to CTLA-4
    Publication number: 20080233116
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 25, 2008
    Applicants: Abgenix, Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Human monoclonal antibodies to CTLA-4
    Publication number: 20080233122
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 25, 2008
    Applicants: Abgenix, Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • CANINE COMBINATION VACCINES
    Publication number: 20080226670
    Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.
    Type: Application
    Filed: November 20, 2007
    Publication date: September 18, 2008
    Applicants: WARNER-LAMBERT COMPANY, PFIZER INC.
    Inventors: Paul J. Dominowski, Joseph C. Frantz, Richard L. Krebs, Shelly L. Shields, Robert Greg Sorensen
  • 1H-pyrazoles useful in therapy
    Patent number: 7425569
    Abstract: Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: September 16, 2008
    Assignee: Pfizer Inc
    Inventors: Paul Anthony Bradley, Kevin Neil Dack, Patrick Stephen Johnson, Sarah Elizabeth Skerratt
  • Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
    Patent number: 7419981
    Abstract: The instant invention relates to a combination of an alpha-2-delta ligand and a PDEV inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. A particularly preferred PDEV inhibitors is sildenafil.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: September 2, 2008
    Assignee: Pfizer Inc.
    Inventors: Mark John Field, Richard Griffith Williams
  • Non-anaphylactogenic IgE fusion proteins
    Patent number: 7420047
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: September 2, 2008
    Assignees: Pfizer Inc., Pfizer Products
    Inventors: Mohamad A. Morsey, Tracy M. Brown
  • 7?-Hydroxyacetyl and 7?-Hydroperoxyacetyl-substituted steroid compounds
    Patent number: 7417140
    Abstract: The present invention involves intermediates, including a 7?-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: August 26, 2008
  • Imidazopyrimidines as transforming growth factor (TGF) inhibitors
    Patent number: 7417041
    Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: August 26, 2008
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
  • ANTIPARASITIC AGENTS
    Publication number: 20080200540
    Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, compositions containing such compounds and the uses of such compounds as antiparasitic agents.
    Type: Application
    Filed: February 20, 2008
    Publication date: August 21, 2008
    Applicant: PFIZER LIMITED
    Inventors: Stephen Paul Gibson, Christelle Lauret
  • Enteric Coated Azithromycin Multiparticulates
    Publication number: 20080199527
    Abstract: A pharmaceutical composition is disclosed which comprises multiparticulates wherein said multiparticulates further comprise an azithromycin core and an enteric coating disposed upon said azithromycin core.
    Type: Application
    Filed: December 9, 2005
    Publication date: August 21, 2008
    Applicant: Pfizer Inc.
    Inventors: William J. Curatolo, Scott M. Herbig, Steven R. LeMott, Julian B. Lo, Leah E. Appel, Dwayne T. Friesen, David K. Lyon, Scott B. McCray, James B. West